MX361893B - Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos. - Google Patents

Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos.

Info

Publication number
MX361893B
MX361893B MX2014006361A MX2014006361A MX361893B MX 361893 B MX361893 B MX 361893B MX 2014006361 A MX2014006361 A MX 2014006361A MX 2014006361 A MX2014006361 A MX 2014006361A MX 361893 B MX361893 B MX 361893B
Authority
MX
Mexico
Prior art keywords
vectors
mdv
gallid herpesvirus
recombinant gallid
recombinant
Prior art date
Application number
MX2014006361A
Other languages
English (en)
Other versions
MX2014006361A (es
Inventor
Mebatsion Teshome
Bublot Michel
Pritchard Joyce
Linz Perry
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47358292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX361893(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Inc filed Critical Merial Inc
Publication of MX2014006361A publication Critical patent/MX2014006361A/es
Publication of MX361893B publication Critical patent/MX361893B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/125—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a vectores recombinantes de herpesvirus 3 gálido (MDV-2) que contienen y expresan antígenos de patógenos de aves, vectores recombinantes de herpesvirus 3 gálido (MDV-2) que contienen un gen gC mutado, composiciones que comprenden los vectores recombinantes de herpesvirus 3 gálido (MDV-2), vacunas polivalentes que comprenden dichos vectores recombinantes de herpesvirus 3 gálido (MDV-2) y uno o más virus de tipo salvaje o vectores recombinantes. Se proveen además métodos de vacunación contra diversos patógenos de aves y para producir los vectores recombinantes de herpesvirus 3 gálido (MDV-2).
MX2014006361A 2011-11-30 2012-11-29 Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos. MX361893B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161564877P 2011-11-30 2011-11-30
US201261694957P 2012-08-30 2012-08-30
PCT/US2012/067123 WO2013082317A2 (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof

Publications (2)

Publication Number Publication Date
MX2014006361A MX2014006361A (es) 2015-03-05
MX361893B true MX361893B (es) 2018-12-18

Family

ID=47358292

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014006360A MX365984B (es) 2011-11-30 2012-11-29 Vectores recombinantes de hvt que expresan antígenos de patógenos de aves y sus usos.
MX2014006361A MX361893B (es) 2011-11-30 2012-11-29 Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014006360A MX365984B (es) 2011-11-30 2012-11-29 Vectores recombinantes de hvt que expresan antígenos de patógenos de aves y sus usos.

Country Status (28)

Country Link
EP (7) EP4112073A1 (es)
JP (1) JP6149301B2 (es)
KR (1) KR102013135B1 (es)
CN (3) CN104159605B (es)
AR (2) AR090401A1 (es)
BR (1) BR112014013276B1 (es)
CA (1) CA2857025C (es)
CO (1) CO7061033A2 (es)
CY (3) CY1121528T1 (es)
DK (3) DK2785373T3 (es)
ES (3) ES2785045T3 (es)
HK (4) HK1248566A1 (es)
HR (3) HRP20190525T4 (es)
HU (3) HUE042471T2 (es)
IN (1) IN2014CN04833A (es)
LT (3) LT3251691T (es)
ME (1) ME03433B (es)
MX (2) MX365984B (es)
PE (1) PE20141482A1 (es)
PH (2) PH12014501174B1 (es)
PL (3) PL3251691T3 (es)
PT (3) PT2785373T (es)
RS (3) RS58610B1 (es)
RU (1) RU2620936C2 (es)
SI (3) SI2785374T1 (es)
UA (1) UA118651C2 (es)
WO (2) WO2013082317A2 (es)
ZA (1) ZA201403804B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201818883T4 (tr) 2011-10-21 2019-01-21 Intervet Int Bv Enfeksiyöz laringotrakeit virüsü ve Newcastle hastalığı virüsü antijenlerini kodlayan rekombinant patojenik olmayan marek hastalığı virüsü yapıları.
IN2014CN04833A (es) 2011-11-30 2015-09-18 Merial Ltd
EP2644702A1 (en) 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
AR097029A1 (es) 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
EP2845904A1 (en) * 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
AR103245A1 (es) * 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
US10537628B2 (en) 2015-08-10 2020-01-21 The Texas A&M University System Recombinant turkey herpesvirus vaccines and uses thereof
HUE061405T2 (hu) 2016-06-17 2023-06-28 Intervet Int Bv Nem patogén Marek-betegség vírus konstruktok, amelyek fertõzõ laryngotracheitis vírus és fertõzõ bursitis vírus antigéneket kódolnak
JOP20190088A1 (ar) * 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
EP3554536B1 (en) * 2016-12-14 2022-10-26 Boehringer Ingelheim Animal Health USA Inc. Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
CN106929483B (zh) * 2017-01-19 2020-09-25 北京邦卓生物科技有限公司 表达鸡新城疫病毒f基因的重组火鸡疱疹病毒的构建及其应用
CN106701693A (zh) * 2017-01-19 2017-05-24 北京邦卓生物科技有限公司 表达血清ⅰ型马立克氏病病毒gb基因的重组火鸡疱疹病毒的构建及其应用
EP3391903B1 (en) * 2017-04-21 2022-02-23 The Pirbright Institute Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogen antigens
CN107099513B (zh) * 2017-06-22 2020-07-14 北京邦卓生物科技有限公司 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN107603958A (zh) * 2017-09-29 2018-01-19 天津农学院 融合表达TM‑1基因和gD基因重组腺病毒的构建方法及重组腺病毒和应用
WO2019072964A1 (en) * 2017-10-12 2019-04-18 Intervet International B.V. RECOMBINANT NON-PATHOGENIC MAREK DISEASE VIRUS CONSTRUCTS ENCODING MULTIPLE HETEROLOGOUS ANTIGENS
JP7448475B2 (ja) 2017-12-20 2024-03-12 インターベット インターナショナル ベー． フェー． 細胞関連アルファヘルペスウイルスワクチン用の改善された希釈液
CN108543067A (zh) * 2017-12-25 2018-09-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 共表达h5亚型禽流感ha蛋白和传染性法氏囊vp2蛋白的重组火鸡疱疹病毒疫苗株
CN111918660A (zh) * 2018-01-24 2020-11-10 复诺健生物科技加拿大有限公司 重组病毒疫苗
CN109468315B (zh) * 2018-12-07 2021-09-07 袁隆平农业高科技股份有限公司 水稻耐淹基因Sub1共显性分子标记及应用
CN113226363A (zh) 2018-12-21 2021-08-06 法国诗华大药厂 含有多个外来基因的重组禽疱疹病毒
EP4028510A1 (en) 2019-09-11 2022-07-20 Zoetis Services LLC Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof
CN110872578B (zh) * 2019-11-29 2022-09-16 扬州优邦生物药品有限公司 一株变异株传染性法氏囊病毒、亚单位疫苗及其制备方法和应用
US11299517B2 (en) * 2020-04-15 2022-04-12 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant vaccine against Marek's disease and Newcastle disease
BR112022025733A2 (pt) 2020-06-17 2023-03-07 Boehringer Ingelheim Vetmedica Gmbh Vetores hvt recombinantes expressando hemaglutinina de influenza e composições imunogênicas, e produção e usos dos mesmos
CN112206317B (zh) * 2020-10-12 2023-09-22 浙江省淡水水产研究所 一种草鱼出血病二价核酸菌蜕疫苗的制备方法
WO2022079160A2 (en) 2020-10-15 2022-04-21 Ceva Sante Animale Recombinant hvt and uses thereof
CN114317827B (zh) * 2022-01-07 2023-03-24 河南省农业科学院 一种鉴别不同血清型马立克病病毒感染与免疫的多重pcr引物、方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
AU623333B2 (en) 1986-01-27 1992-05-14 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
JP2779447B2 (ja) 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
BE1004877A3 (fr) 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
US6183753B1 (en) 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
US5853733A (en) 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
FR2719056B1 (fr) 1994-04-20 1996-09-06 Rhone Merieux Herpesvirus transformés pour exprimer gD in vitro.
ES2360298T3 (es) * 1994-08-09 2011-06-02 Schering-Plough Ltd. Herpesvirus recombinantes de pavos y sus usos.
RU2059414C1 (ru) * 1994-12-09 1996-05-10 Государственная Курская биофабрика - Фирма "БИОК" Поливалентная вакцина для профилактики болезни марека и способ ее изготовления
FR2728795B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
JPH104956A (ja) * 1996-06-21 1998-01-13 Univ Michigan State マレク病ワクチン製造のための維持可能な細胞株の改良
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
AU4992197A (en) 1996-10-11 1998-05-11 Regents Of The University Of California, The Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
DE69836557T2 (de) * 1997-10-03 2007-09-20 Zeon Corp. Rekombinanten des infektiösen vogel-herpesvirus und rekombinante impfstoffe, die unter dessen verwendung hergestellt wurden
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
KR100354972B1 (ko) 2000-04-11 2002-10-05 대한민국 닭전염성기관지염 바이러스 ｓ1 단백질을 발현하는유전자재조합 마렉바이러스 및 그의 제조방법
US6764684B2 (en) 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
US6866852B2 (en) 2002-01-31 2005-03-15 Zeon Corporation Recombinant herpesvirus of turkeys and use thereof
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
WO2010119112A1 (en) * 2009-04-15 2010-10-21 Ceva Sante Animale Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
IN2014CN04833A (es) 2011-11-30 2015-09-18 Merial Ltd

Also Published As

Publication number Publication date
CY1122872T1 (el) 2021-05-05
CY1124618T1 (el) 2022-03-24
CY1121528T1 (el) 2020-05-29
CA2857025C (en) 2021-08-03
EP2785374A2 (en) 2014-10-08
JP6149301B2 (ja) 2017-06-21
ES2719409T5 (es) 2022-12-07
HRP20192215T1 (hr) 2020-02-21
PT2785373T (pt) 2020-01-27
EP3263130A1 (en) 2018-01-03
DK2785374T3 (en) 2019-04-08
PH12014501174A1 (en) 2014-09-08
RU2014126375A (ru) 2016-01-27
ES2775218T3 (es) 2020-07-24
HRP20190525T8 (hr) 2023-01-20
RS58610B1 (sr) 2019-05-31
LT2785374T (lt) 2019-04-25
PT3251691T (pt) 2020-01-28
PH12015502790A1 (en) 2017-07-10
HK1248566A1 (zh) 2018-10-19
CN104159604B (zh) 2016-08-24
LT3251691T (lt) 2020-02-10
PH12014501174B1 (en) 2014-09-08
EP3578199A1 (en) 2019-12-11
CN104159604A (zh) 2014-11-19
RU2620936C2 (ru) 2017-05-30
WO2013082317A3 (en) 2013-08-15
CN104159605B (zh) 2019-04-19
EP3251691B1 (en) 2019-11-20
HUE047724T2 (hu) 2020-05-28
PL2785373T3 (pl) 2020-06-01
BR112014013276A2 (pt) 2018-05-15
SI2785373T1 (sl) 2020-02-28
LT2785373T (lt) 2020-02-10
IN2014CN04833A (es) 2015-09-18
EP2785373B1 (en) 2019-11-20
PE20141482A1 (es) 2014-11-08
PL2785374T3 (pl) 2019-07-31
WO2013082327A1 (en) 2013-06-06
EP3572092A1 (en) 2019-11-27
WO2013082317A8 (en) 2014-07-10
EP3251691A1 (en) 2017-12-06
CA2857025A1 (en) 2013-06-06
CN105920598A (zh) 2016-09-07
CO7061033A2 (es) 2014-09-19
PL3251691T3 (pl) 2020-06-01
HUE047909T2 (hu) 2020-05-28
PT2785374T (pt) 2019-05-09
BR112014013276B1 (pt) 2021-07-27
KR102013135B1 (ko) 2019-08-22
WO2013082327A8 (en) 2014-07-03
EP2785373A1 (en) 2014-10-08
DK2785373T3 (da) 2020-02-03
AR090401A1 (es) 2014-11-12
EP4112073A1 (en) 2023-01-04
HRP20192241T1 (hr) 2020-03-06
EP2785374B2 (en) 2022-08-17
UA118651C2 (uk) 2019-02-25
HUE042471T2 (hu) 2019-07-29
WO2013082317A2 (en) 2013-06-06
ES2785045T3 (es) 2020-10-05
MX2014006361A (es) 2015-03-05
ME03433B (me) 2020-01-20
EP2785374B1 (en) 2019-01-09
AR089039A1 (es) 2014-07-23
HK1197175A1 (en) 2015-01-09
HRP20190525T1 (hr) 2019-05-03
HRP20190525T4 (hr) 2023-01-20
HK1247832A1 (zh) 2018-10-05
HK1200018A1 (en) 2015-07-31
RS59893B1 (sr) 2020-03-31
ES2719409T3 (es) 2019-07-10
MX2014006360A (es) 2015-03-05
RS59892B1 (sr) 2020-03-31
MX365984B (es) 2019-06-21
SI3251691T1 (sl) 2020-02-28
CN104159605A (zh) 2014-11-19
ZA201403804B (en) 2015-04-29
JP2015500806A (ja) 2015-01-08
PL2785374T5 (pl) 2023-01-09
PH12015502790B1 (en) 2017-07-10
DK3251691T3 (da) 2020-02-10
KR20140097515A (ko) 2014-08-06
SI2785374T1 (sl) 2019-04-30

Similar Documents

Publication Publication Date Title
MX361893B (es) Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos.
PH12019501366A1 (en) Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
EP3012322A4 (en) GENEELED STRAIN VARIANT OF PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF
MX2016016722A (es) Coronavirus.
MY187462A (en) Modified virus-like particles of cmv
MX352974B (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
PH12019500854A1 (en) Recombinant vectors expressing antigens of avian influenza virus and uses thereof
EP4286002A3 (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
TN2014000518A1 (en) Reassortant btv and ahsv vaccines
ZA201603187B (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
MX338052B (es) Vectores de parapoxvirus que contienen el antigeno del virus de la rabia.
MX2013000787A (es) Vectores de parapoxvirus.
MX2018013358A (es) Vacunas para el virus del papiloma humano y metodos para su uso.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: MERIAL, INC.